title: [Erlotinib, sunitinib, and everolimus].
authors: Masanobu
authors: M
authors: Takahashi
mesh_terms: D000970:Antineoplastic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D017326:Clinical Trials, Phase III as Topic; D000069347:Erlotinib Hydrochloride; D000068338:Everolimus; D006801:Humans; D007211:Indoles / Q000009:adverse effects / Q000627:therapeutic use*; D010190:Pancreatic Neoplasms / Q000188:drug therapy*; D011758:Pyrroles / Q000009:adverse effects / Q000627:therapeutic use*; D011799:Quinazolines / Q000009:adverse effects / Q000627:therapeutic use*; D020123:Sirolimus / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use; D000077210:Sunitinib
chemical_list: D000970:Antineoplastic Agents; D007211:Indoles; D011758:Pyrroles; D011799:Quinazolines; D000068338:Everolimus; D000069347:Erlotinib Hydrochloride; D000077210:Sunitinib; D020123:Sirolimus